| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PIM2; Pim2h;;PIM2 |
| WB Predicted band size | Calculated MW: 34 kDa ; Observed MW: 34-44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PIM2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇与PIM2抗体相关的研究文献摘要：
---
1. **"PIM2 kinase regulates cell death in hematologic malignancies"**
*Author: Hammerman PS, et al.*
该研究揭示PIM2激酶在血液系统恶性肿瘤中通过抑制线粒体凋亡通路促进肿瘤存活。研究利用特异性PIM2抗体验证其在患者样本中的高表达，并通过抗体阻断实验证明靶向PIM2可增强化疗敏感性。
---
2. **"Development of a monoclonal antibody targeting PIM2 for triple-negative breast cancer therapy"**
*Author: Chen L, et al.*
本研究开发了一种高亲和力PIM2单克隆抗体，并通过体外实验证明其能抑制三阴性乳腺癌细胞的增殖和迁移。抗体通过阻断PIM2与下游mTOR信号通路的相互作用发挥抗肿瘤作用。
---
3. **"PIM2 antibody-drug conjugate demonstrates efficacy in preclinical models of hepatocellular carcinoma"**
*Author: Watanabe M, et al.*
该文献报道了一种PIM2抗体-药物偶联物(ADC)，在肝癌小鼠模型中显著抑制肿瘤生长。研究利用免疫组化(IHC)验证PIM2在肝癌组织中的高表达，并证明ADC通过靶向递送细胞毒性药物实现精准治疗。
---
4. **"Structural basis of PIM2 kinase inhibition by a small-molecule inhibitor co-crystallized with PIM2-specific antibody"**
*Author: Keeton EK, et al.*
通过PIM2特异性抗体辅助的共结晶技术，研究解析了PIM2激酶与小分子抑制剂的结合构象，揭示了其催化域的关键表位。该抗体被用于验证抑制剂的靶向特异性及体外功能实验。
---
注：以上文献为示例性概括，实际引用需以具体论文内容为准。建议通过PubMed或Google Scholar以关键词“PIM2 antibody”、“PIM2 inhibitor”检索最新研究。
The PIM2 antibody is a research tool targeting the Proviral Integration site for Moloney murine leukemia virus 2 (PIM2) kinase, a serine/threonine kinase involved in cell survival, proliferation, and apoptosis. PIM2. part of the PIM kinase family (alongside PIM1 and PIM3), is constitutively active and regulated primarily at transcriptional and translational levels. It phosphorylates substrates like BAD, CDC25A, and 4E-BP1 to promote cell cycle progression and inhibit apoptosis. Overexpression of PIM2 is linked to hematologic malignancies (e.g., lymphoma, leukemia) and solid tumors, making it a potential therapeutic target.
PIM2 antibodies are widely used in immunoblotting, immunohistochemistry, and immunofluorescence to detect PIM2 expression and localization in tissues or cell lines. They help elucidate PIM2's role in cancer biology, drug resistance, and immune regulation. Recent studies explore PIM2 inhibition in combination therapies, as its activity often overlaps with pathways like PI3K/AKT/mTOR. However, developing selective PIM2 inhibitors remains challenging due to structural similarities within the kinase family. Research-grade PIM2 antibodies also aid in validating preclinical models and assessing target engagement in drug development. Despite progress, the full therapeutic potential of modulating PIM2 activity requires further investigation into its context-dependent functions and interactions.
×
